Patents by Inventor Ganesh Madhusudan Sathe
Ganesh Madhusudan Sathe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6358695Abstract: HNEAA81 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are screening methods for identifying agonists and antagonists of the interaction of the HNEAA81 receptor and its ligands in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: April 26, 2000Date of Patent: March 19, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham plcInventors: Ganesh Madhusudan Sathe, Wendy S Halsey, Jon Chambers, Alison Muir, Philip Szekeres
-
Patent number: 6328974Abstract: This invention relates to immunogenic compositions capable of potentiality growth hormone activity, comprising an immunologically effective amount of a composite peptide comprising at least two non-contiguous somatotropin epitope amino acid sequences, wherein said composite peptide is substantially free of receptor binding domain sequences; and an immunologically acceptable excipient. The invention further relates to methods of using an immunogenic composition of the invention to potentiate the action of growth hormone in pigs.Type: GrantFiled: March 26, 1999Date of Patent: December 11, 2001Assignee: Pfizer IncInventors: Hector Wasunna Alila, Michael Thomas Clark, Elaine Verne Jones, Timothy Joe Miller, Shawn Patrick O'Brien, Ganesh Madhusudan Sathe
-
Publication number: 20010021509Abstract: HNEAA81 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are screening methods for identifying agonists and antagonists of the interaction of the HNEAA81 receptor and its ligands in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: ApplicationFiled: January 24, 2001Publication date: September 13, 2001Inventors: Ganesh Madhusudan Sathe, Wendy S. Halsey, Jon Chambers, Alison Muir, Philip Szekeres
-
Patent number: 6277977Abstract: HAPOI67 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HAPOI67 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: October 23, 1997Date of Patent: August 21, 2001Assignee: SmithKline Beecham CorporationInventors: Ganesh Madhusudan Sathe, Joyce Yue Mao
-
Patent number: 6162899Abstract: HNEAA81 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are screening methods for identifying agonists and antagonists of the interaction of the HNEAA81 receptor and its ligands in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: December 28, 1999Date of Patent: December 19, 2000Assignees: SmithKline Beecham Corporation, SmithKline Beecham plcInventors: Ganesh Madhusudan Sathe, Wendy S Halsey, Jon Chambers, Alison Muir, Philip Szekeres
-
Patent number: 5976834Abstract: HNFJD15 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HNFJD15 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: January 9, 1997Date of Patent: November 2, 1999Assignee: SmithKline Beecham CorporationInventors: Ganesh Madhusudan Sathe, Wendy S. Fuetterer, Derk John Bergsma, Catherine Ellis
-
Patent number: 5889144Abstract: This invention relates to composite somatotropin peptides comprising somatotropin epitopic amino acid sequences, and fusion proteins thereof, useful in potentiating growth hormone activity. Also disclosed are vectors and host cells useful in the recombinant production of such molecules. Vaccines containing the composite somatotropin peptides and fusion proteins of the present invention, and methods of using the same, are disclosed.Type: GrantFiled: April 30, 1997Date of Patent: March 30, 1999Assignee: Pfizer Inc.Inventors: Hector Wasunna Alila, Michael Thomas Clark, Elaine Verne Jones, Timothy Joe Miller, Shawn Patrick O'Brien, Ganesh Madhusudan Sathe
-
Patent number: 5874243Abstract: OLRCC15 receptor polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing OLRCC15 receptor polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: March 28, 1997Date of Patent: February 23, 1999Assignee: SmithKline Beecham CorporationInventors: Roberto Anibal Macina, Ganesh Madhusudan Sathe
-
Patent number: 5686268Abstract: This invention relates to composite somatotropin peptides and fusion protein thereof useful in the potentiating of growth hormone activity. Also disclosed are vector and host cells useful in the recombinant production of such molecules. Vaccines containing composite somatotropin and fusion proteins thereof and methods of using same as disclosed.Type: GrantFiled: January 27, 1995Date of Patent: November 11, 1997Assignee: Pfizer Inc.Inventors: Hector Wasunna Alila, Michael Thomas Clark, Elaine Verne Jones, Timothy Joe Miller, Shawn Patrick O'Brien, Ganesh Madhusudan Sathe